• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Research Brief on 7-Bromo-3-iodo-quinoline (CAS: 1416440-61-3): Recent Advances and Applications in Chemical Biology and Drug Discovery

7-Bromo-3-iodo-quinoline (CAS: 1416440-61-3) is a halogenated quinoline derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and medicinal chemistry. This compound serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and antimicrobial agents. Recent studies have highlighted its potential in targeted drug design, leveraging its unique structural features for selective protein binding and functional modulation.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 7-bromo-3-iodo-quinoline as a scaffold for developing selective inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase. The researchers utilized palladium-catalyzed cross-coupling reactions to introduce diverse substituents at the 3-iodo position, yielding compounds with nanomolar potency against EGFR-mutant non-small cell lung cancer cells. This work underscores the compound's value in structure-activity relationship (SAR) studies for oncology drug discovery.

In the realm of infectious disease research, 7-bromo-3-iodo-quinoline has shown promise as a precursor for antimalarial agents. A recent publication in Bioorganic & Medicinal Chemistry Letters reported its conversion into novel 4-aminoquinoline derivatives with potent activity against chloroquine-resistant Plasmodium falciparum strains. The electron-withdrawing effects of the bromo and iodo substituents were found to significantly influence the compounds' pharmacokinetic properties and parasite killing efficiency.

From a synthetic chemistry perspective, advances in transition metal-catalyzed functionalization have expanded the utility of 7-bromo-3-iodo-quinoline. A 2024 study in Advanced Synthesis & Catalysis described a regioselective borylation protocol that preserves both halogen atoms while introducing boron functionality at the C5 position. This methodology enables rapid diversification of the quinoline core for high-throughput screening of bioactive compounds.

The compound's photophysical properties have also been investigated for potential applications in bioimaging. Researchers have developed 7-bromo-3-iodo-quinoline-based fluorescent probes that exhibit solvatochromic behavior, making them useful for monitoring microenvironment changes in cellular systems. These probes have been particularly valuable in studying membrane dynamics and protein aggregation phenomena.

In conclusion, 7-bromo-3-iodo-quinoline (1416440-61-3) continues to be a valuable building block in medicinal chemistry, with recent research expanding its applications across multiple therapeutic areas. Its unique halogenation pattern offers multiple sites for selective modification, while the quinoline core provides favorable pharmacokinetic properties. Ongoing studies are exploring its potential in PROTAC design and covalent inhibitor development, suggesting this compound will remain relevant in future drug discovery efforts.

• 123020-20-2(5-Bromo-7-iodo-1H-indole)
• 927801-23-8(6-bromo-4-iodo-quinoline)
• 1416440-23-7(6-bromo-3-iodo-quinoline)
• 608143-12-0(4-bromo-8-iodoquinoline)
• 885519-17-5(6-Bromo-4-iodo-1H-indole)
• 850334-30-4(4-Bromo-6-iodo-1H-indole)
• 700871-87-0(7-bromo-4-iodo-quinoline)
• 1078160-90-3(6-Bromo-8-iodoquinoline)
• 917251-85-5(8-bromo-3-iodo-quinoline)
• 1416438-35-1(5-bromo-3-iodo-quinoline)